Chiesi has taken the lead in making an upfront investment in a new platform of inhalers, called the carbon minimal inhalers, ...

The Medtech sector is at a critical moment, where innovation and regulation must coexist. A stricter regulatory environment ...

The antibody-drug conjugate (ADC) is currently under review by the FDA as a treatment for advanced or metastatic non-squamous ...

In final draft guidance due to be finalised before the end of the month, Welireg (belzutifan) has been recommended as an ...

MSD's PD-1 inhibitor Keytruda has ruled the immunotherapy of non-small cell lung cancer (NSCLC) for many years, but a ...

MSD and Daiichi Sankyo started enrolling patients into the phase 3 Ideate-Lung02 study in the summer.

Pfizer and BioNTech have been among the leaders in the race to bring a combined COVID-19 and influenza vaccine to market, but have stumbled in the final straight. The companies reported mixed ...

Liver disease is on the rise around the world, posing a significant health concern. Fortunately, more and more pharmaceutical companies and academics are striving to create increasingly effective ...

MSD has an extensive pipeline in oncology but hasn't been a player in bispecific antibodies. Now, it has bolted on a bispecific via a $1.3 billion licensing deal with Curon Biopharma. The big ...

The only antiviral recognised as an mpox treatment was unable to shorten the time to resolution of lesions in a trial in the Democratic Republic of the Congo (DRC), the epicentre of an outbreak ...

Geron's first-in-class cancer drug Rytelo, recently approved by the FDA for myelodysplastic syndromes (MDS), is priced three to four times higher than it should be, according to the Institute for ...

The Missouri case was detected through routine flu season surveillance, said the CDC, and is also the first time that an H5 ...